908 Devices Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced preliminary unaudited financial results for the quarter and full year ended December 31, 2024.
Getinge and 908 Devices Partner to Enhance Bioreactor Capabilities for Continuous Monitoring of Key Cell Culture Parameters
Today, 908 Devices Inc. (Nasdaq: MASS) and Getinge announce their collaboration to integrate Getinge’s bioreactors with 908 Devices’ MAVEN for automated control of glucose and lactate levels in cell cultures. The combined solution will help scientists measure critical process parameters in bioreactors, offering continuous, real-time analysis without the need for manual sampling.
908 Devices Reports Third Quarter 2024 Financial Results and Updates 2024 Revenue Outlook
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended September 30, 2024.
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the following investor conferences.
908 Devices to Report Third Quarter 2024 Financial Results on November 12, 2024
908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, November 12, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.
908 Devices to Participate in Craig-Hallum Bioprocessing Conference
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the upcoming virtual Craig-Hallum Bioprocessing Conference.
908 Devices Reports Second Quarter 2024 Financial Results and Reiterates 2024 Revenue Outlook
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today reported financial results for the quarter ended June 30, 2024.
908 Devices to Participate in Canaccord Genuity 44th Annual Growth Conference
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced it will participate in the upcoming Canaccord Genuity 44th Annual Growth Conference.
908 Devices to Report Second Quarter 2024 Financial Results on August 6, 2024
908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical analysis, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, August 6, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.
908 Devices Appoints Michele M. Leonhart, Former Administrator of the United States Drug Enforcement Administration (DEA), to Its Board of Directors
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, has appointed Michele M. Leonhart, the former Administrator of the United States Drug Enforcement Administration (DEA), to serve on its Board of Directors effective immediately.
908 Devices Enhances XplorIR Portable Analyzer to Simultaneously Identify and Quantify Hazardous Gases and Vapors
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical analysis, today announced an enhanced quantification package for its XplorIR handheld gas and vapor analyzer. With this software update, the device, part of 908 Devices’ acquisition of RedWave Technology, can now quantify nearly 5,000 airborne chemicals. XplorIR empowers fire departments, HAZMAT teams and other first responders with mission-critical information and enables decisions around personal protective equipment, ensures swift remediation efforts and reduces dangers to first responders and the public.
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences.
908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended March 31, 2024.
908 Devices Acquires RedWave Technology, Expanding its Forensics Product Offering
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biochemical analysis, announces that it has completed the acquisition of privately-held RedWave Technology, a leading provider of portable FTIR spectroscopic analyzers for rapid chemical identification of bulk materials. FTIR (Fourier Transform Infrared), an optical spectroscopy technology, is highly regarded for its specific substance identification abilities across a broad range of bulk materials.
908 Devices to Report First Quarter 2024 Financial Results on April 30, 2024
908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.
908 Devices Trace Chemical Identification Technology Adopted by European Agencies
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces the latest in international adoption of the MX908 for trace detection and identification of priority drugs and chemical threats. DrugDetect EU and NATO Support and Procurement Agency (NSPA) have both entered into new contracts to deploy the MX908, a handheld high-pressure mass spectrometry (HPMS) device. The MX908 will be used in a variety of settings, from military applications to correctional facilities.
908 Devices Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Revenue Outlook
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter and full year ended December 31, 2023.
908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares’ Fully Integrated Cell Therapy Manufacturing Platform
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and commercial-scale cell therapy manufacturing, announce a development collaboration to integrate in-line monitoring of key cell culture parameters into Cellares’ Cell Shuttle system, a fully integrated, scalable, cell therapy manufacturing platform. The collaboration between the two companies aims to further advance the efficiency, safety, and cost-effectiveness of large-scale cell therapy manufacturing.
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences.
908 Devices to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and desktop devices for chemical and biochemical analysis, today announced it will report financial results for the fourth quarter and full year 2023 before market open on Tuesday, March 5, 2024. Company management will webcast a corresponding conference call beginning at 8:30 a.m. Eastern Time / 5:30 a.m. Pacific Time.
908 Devices Announces MX908 Integration Capabilities
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced that it has expanded access to its leading trace detection technology in its handheld MX908 device through the addition of a weatherproof, digital communications port, thereby enabling companies to integrate the device into their systems to enhance the safety of their users and the public.
908 Devices Reports Third Quarter 2023 Financial Results and Narrows 2023 Revenue Outlook
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today reported financial results for the quarter ended September 30, 2023.
908 Devices and Terumo Blood and Cell Technologies Collaborate to Add On-line Analytics to Quantum Flex Cell Expansion System
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and medical technology company Terumo Blood and Cell Technologies (Terumo BCT) announce a collaboration to enable on-line monitoring of critical process parameters in Terumo BCT’s Quantum Flex Cell Expansion System. The combination of the companies’ automation technologies will help advance the development of life-saving cell and gene therapies by providing insights into and control of one of the largest components of cell therapy development and manufacturing.
908 Devices to Participate in Upcoming Investor Conferences
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, today announced it will participate in the following investor conferences.
908 Devices Awarded $10.4M Order from the United States Air Force for its Handheld MX908 Device
908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, announces today that it has been awarded a total of $10.4 million in purchase orders from the United States Air Force and Air National Guard Fire & Emergency Services Program for its MX908 handheld mass spectrometry device with Aero module.
